PTC Therapeutics
Budget
€200 — €0
EP Access
0
accredited persons
Staff
1
0.5 FTE
EU Grants
None
Mission & Goals
Our mission at PTC Therapeutics has always been to build an integrated biopharmaceutical company based on our expertise in RNA biology. We have focused on discovering and developing novel oral treatments for patients with serious and life-limiting disorders. By targeting the processes that modulate RNA biology and affect protein production, we bring an innovative approach to drug discovery. We are focused particularly on the development of treatments for rare and neglected disorders.
EU Legislative Interests
We follow EU initiatives, policies and legislation relating to the pharmaceutical industry and specifically treatments for rare diseases and policies for orphan medicines and advanced therapy medicinal products, such as cell and gene therapies. In particular, but not exclusively, we are interested in: European Biotech Act, Critical Medicines Act, the General Pharmaceutical legislation, Orphan Medicines legislation, the EU Life Science Act and cross border health legislation
Communication Activities
Mainly by way of participation in events organised by Industry Associations, Multistakeholder platforms, Thinks Tanks, Patient Groups. We participate in panels organised by Europabio, EUCOPE and Transform, representing industry or PTC to reflect our views on the above EU policies. PTC has also presented at conferences such as the WODC and public health Gastein on similar subjects.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
EuropaBio https://www.europabio.org/ EUCOPE https://www.eucope.org/ TRANSFORM https://transformalliance.eu/ European Group of Experts on OMP Incentives https://od-expertgroup.eu/ EU Biotech and Life Sciences Alliance. https://biolifesciences.eu/
Commissioner Meetings
No recorded meetings with EU commissioners.